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Background
Pediatric Sarcoidosis is a rare multisystem granuloma-
tous disorder and series from the Asian subcontinent
are few.
Aim
We describe our experience to date with an inceptional
cohort.
Methods
Retrospective chart review of the demographic, clinical,
diagnostic and genetic characteristics were studied.
Results
Over seven years, 12 of 1214 new cases seen in the
Pediatric Rheumatology Clinic (1%) (M: F = 1:1), were
diagnosed as Sarcoidosis. 11/12(91.7%) had an onset ≤4
years of age, 8/12(67%) maintained a cumulative follow-
up of 33.7 years ( range 1-9 years). 7/12(58.3%) had
received anti-tuberculous therapy prior to referral.
Diagnosis was by clinical presentation ‘plus’:A C E( 4 /
12), biopsy (1/12), biopsy and ACE (3/12), biopsy and
mutation (1/12), mutation (2/12). 3/9(33.3%) are positive
for CARD15 mutation (Blau Syndrome). 2 have sporadic
mutations at R334W while 1 with a mutation at
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Table
Cohort features Characteristics at Onset/ 1
st visit Follow-up ( ≥ 1 year)
Number(N)
Median age (years) [IQR]
12
Onset:1.25[0.9-1.7]Diagnosis:7.8[4.9-9.9]
8
Fever; median duration 10/12(83.3%);18 months Resolution
Arthritis 7/12(58.3%) Resolution
Skin manifestations 7/12(58.3%) Resolved 6/8(75%)
Ocular abnormalities Onset: 6/12(50%), 1st visit: 5/6(83.3%) 2/5(40%)
Triad-Arthritis,Rash,Uveitis Onset: 5/12(41.7%), 1st visit: 3/5(60%) None
Systemic features Sicca(1),Adenopathy(4),GIT(4), Pulmonary(5),
Organomegaly(9)
Aortoarteritis(1/8)
Interstitial lung(1/8)
Growth retardation 12/12(100%) 5/8(62.5%)
Median Steroid dose(mg/kg/day) [IQR]
Median Methotrexate dose(mg/m2BSA)
[IQR]
Others:
0.6[0.2-0.8]
10.1[0-10.4]
0.3[0.1-0.3]
10.9[9.7-15.3]
Azathioprine(vasculitic rash)(1),Mycophenolate
(uveitis)(1)
Treatment side-effects - Hepatotoxicity(1/8) Osteoporosis(2/8)
Cataracts(3/8)
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and has a symptomatic parent with the identical muta-
tion. None of the 8 patients following up are off therapy.
5/8(62.5%) achieved clinical improvement in a median
duration of 6.9 months[5.6-9.6 IQR].
Conclusions
In our setting, Pediatric Sarcoidosis had a significant
time lag to diagnosis, being often initially diagnosed as
tuberculosis owing to similar clinical picture and histol-
ogy. Morbidity is considerable, with arthritis, fever and
rash responding to therapy while eye changes and organ
damage are relatively refractory. All children show sig-
nificant growth retardation at diagnosis and follow up
inspite of control of constitutional features. Amongst
the 3 Blau Syndrome patients, one had an atypical pre-
sentation and an autosomal dominant inheritance.
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